Psoríase como fator de risco para doenças cardiovasculares: uma revisão da literatura / Psoriasis as a risk factor for cardiovascular disease: a literature review

Henrique Guimarães Vasconcelos, Lucas Emmels Malaquias, Diego Marquesi Costa Roque, Yuri da Silva Brasil, Gustavo Fajardo Cury Fávero, Mariana Menezes de Resende Vieira, Ediane Cristina Carrera Eleres da Costa, Izaias Gomes da Silva Júnior, Rafael Augusto Moreira André, Anna Cláudia Cardoso Neves, Manuela Xavier Cajado Sampaio, Gabriella Damares Sousa Silva

Abstract


A psoríase consiste em uma das doenças inflamatórias imunomediadas mais comuns em seres humanos, com prevalência variando de 0,11% a 8,5% na dependência da população analisada. A investigação da associação entre psoríase e fatores de risco para a saúde cardiovascular foi iniciada no último século e, desde então, pesquisas têm apresentado resultados variados. Entretanto, recentes meta-análises e estudos de coorte confirmaram que se trata de uma associação estatisticamente significativa. Os artigos utilizados nesta revisão bibliográfica foram pesquisados nas bases de dados National Library of Medicine (PubMED), Google Acadêmico e Literatura Latino-Americana e do Caribe em Ciências da Saúde (LILACS) e publicados entre os anos 2000 e 2021. Novas evidências científicas reforçam a existência de associação da psoríase com comorbidades que elevam o risco de o indivíduo desenvolver doenças cardiovasculares, incluindo componentes da síndrome metabólica, como diabetes, hipertensão arterial sistêmica, obesidade e dislipidemia. Em razão de a psoríase relacionar-se a um estado de inflamação sistêmica que gera repercussões no aparelho cardiovascular, é importante conscientizar os profissionais médicos sobre a aterosclerose em pacientes psoriáticos, para que intervenções terapêuticas precoces e medidas preventivas possam ser implementadas.


Keywords


Psoríase, Cardiologia, Dermatologia.

References


AHLEHOFF O, et al. Psoriasis is associated writ clinically significant cardiovascular risk: A Danish nationwide cohort study. J. Intern. Med., 2011; 270: 147-157.

AHLEHOFF O, et al. Risk of thromboembolism and fatal stroke in patients with psoriasis and nonvalvular atrial fibrillation: A Danish nationwide cohort study. J. Intern. Med., 2015; 277: 447-455.

BENSON MM, FRISHMAN WH. The heartbreak of psoriasis: A review of cardiovascular risk in patients with psoriasis. Cardiol. Rev., 2015; 23: 312-316.

CAIAZZO G, et al. Psoriasis, cardiovascular events, and biologics: lights and shadows. Frontiers in immunology, 2018; 9: 1668.

DEY AK, et al. Association between skin and aortic vascular inflammation in patients with psoriasis: A case-cohort study using positron emission tomography/computed tomography. JAMA Cardiol., 2017; 2: 1013-1018.

DOWLATSHAHI EA, et al. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: A systematic review and meta-analysis. J. Investig. Dermatol., 2014: 134: 1542-1551.

DREGAN A, et al. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: A population-based cohort study. Circulation, 2014; 130: 837-844.

FURUE M, et al. Cardiovascular and Metabolic diseases comorbid with psoriasis: Beyond the skin. Intern. Med., 2017; 56: 1613-1619.

GELFAND JM, et al. Risk of myocardial infarction in patients with psoriasis. JAMA, 2006; 296: 1735-1741.

GELFAND JM, et al. The risk of stroke in patients with psoriasis. J. Investig. Dermatol., 2009; 129: 2411-2418.

GHAZIZADEH R, et al. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. International Journal of Medical Sciences, 2010; 7(5): 284-289.

HJULER KF, et al. Increased prevalence of coronary artery disease in severe psoriasis and severe atopic dermatitis. Am. J. Med., 2015; 128: 1325-1334.

HU SCS, LAN CCE. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. International Journal of Molecular Sciences, 2017; 18(10): 2211.

JINDAL S, JINDAL N. Psoriasis and cardiovascular diseases: a literature review to determine the causal relationship. Cureus, 2018; 10(2): e2195.

JUNG KJ, et al. Increased risk of atherosclerotic cardiovascular disease among patients with psoriasis in Korea: A 15?year nationwide population?based cohort study. The Journal of dermatology, 2019; 46(10): 859-866.

KORMAN NJ. Management of psoriasis as a systemic disease: what is the evidence?. British Journal of Dermatology, 2020; 182(4): 840-848.

LANGAN SM, et al. Prevalence of metabolic syndrome in patients with psoriasis: A population-based study in the United Kingdom. J. Investig. Dermatol., 2012; 132: 556-562.

MANOLIS AA, et al. Psoriasis and cardiovascular disease: the elusive link. International reviews of immunology, 2019; 38(1): 33-54.

MASSON W, et al. Psoriasis and cardiovascular risk: a comprehensive review. Advances in therapy, 2020; 37(5): 2017-2033.

MILLER IM, et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J. Am. Acad. Dermatol., 2013; 69: 1014-1024.

OGDIE A, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study. Ann. Rheum. Dis., 2015; 74: 326-332.

QUINTARD B, et al. Validation of a specific health-related quality of life instrument in a large cohort of patients with psoriasis: The QualiPso Questionnaire. Acta Derm. Venereol, 2011; 91: 660-665.

SAMARASEKERA EJ, et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. Journal of Investigative Dermatology, 2013; 133(10): 2340-2346.

SHAH K, et al. Real-world burden of comorbidities in US patients with psoriasis. J. Am. Acad. Dermatol., 2017; 77: 287-292.

SHAHWAN KT, KIMBALL AB. Psoriasis and cardiovascular disease. Med. Clin. N. Am., 2015; 99: 1227-1242.

SONDERMANN W, et al. Psoriasis, cardiovascular risk factors and metabolic disorders: sex?specific findings of a population?based study. Journal of the European Academy of Dermatology and Venereology, 2020; 34(4): 779-786.

SU YS, et al. Psoriasis as initiator or amplifier of the systemic inflammatory march: Impact on development of severe vascular events and implications for treatment strategy. J. Eur. Acad. Dermatol. Venereol., 2013; 27: 876-883.

TAKESHITA J, et al. Effect of psoriasis severity on hypertension control: A population-based study in the United Kingdom. JAMA Dermatol., 2015; 151: 161-169.

TAKESHITA J, et al. Psoriasis and comorbid diseases: Epidemiology. J. Am. Acad. Dermatol., 2017; 76: 377-390.

TORRES T, BETTENCOURT N. Psoriasis: the visible killer. Revista Portuguesa de Cardiologia, 2014; 33(2): 95-99.

WAKKEE M, et al. Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: Results of a large population-based Dutch cohort. J. Investig. Dermatol., 2010; 130: 962-967.

YU XL, et al. Psoriasis, cardiovascular disease, and adipokines. Zhongguo yi xue ke xue Yuan xue bao. Acta Academiae Medicinae




DOI: https://doi.org/10.34117/bjdv7n10-298

Refbacks

  • There are currently no refbacks.